|
Title
|
|
|
|
First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening thrombotic microangiopathy, characterized by disseminated thrombus formation in the microvasculature, causing severe organ failure. Immune-mediated TTP (iTTP) is occasionally described after vaccination, especially against viral agents. We report a case of a 38-year-old woman with a de novo iTTP after exposure to the mRNA-based anti-coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer-BioNTech. She presented with increased bruising and petechiae starting 2 weeks after receiving the first dose of the anti-COVID-19 vaccine. Laboratory data revealed a severe ADAMTS13-deficiency in combination with a very high autoantibody titer against ADAMTS13. She was successfully treated with plasma exchange, corticosteroids, rituximab, and caplacizumab. To our knowledge, this is the first case report of iTTP after mRNA-based COVID-19 vaccination in a previously TTP-naive patient. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Journal of thrombosis and haemostasis. - Oxford
|
|
|
Publication
|
|
|
|
Hoboken
:
Wiley
,
2021
|
|
|
ISSN
|
|
|
|
1538-7933
|
|
|
DOI
|
|
|
|
10.1111/JTH.15418
|
|
|
Volume/pages
|
|
|
|
19
:8
(2021)
, p. 2014-2018
|
|
|
ISI
|
|
|
|
000669690100001
|
|
|
Pubmed ID
|
|
|
|
34105244
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|